Erythrocytosis-inducing PHD2 mutations implicate biological role for N-terminal prolyl-hydroxylation in HIF1α oxygen-dependent degradation domain
eLife · 2025
DOI: 10.7554/elife.107121 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Cassandra C Taber und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Hypoxia-Inducible Factor-Proline Dioxygenases, Polycythemia, Hypoxia-Inducible Factor 1, alpha Subunit, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Mutations in EGLN1 , the gene encoding for hypoxia-inducible factor (HIF) prolyl-4-hydroxylase 2 (PHD2), cause erythrocytosis and in rare cases the development of neuroendocrine tumors. In the presence of oxygen, PHD2 hydroxylates one or both conserved prolines in the oxygen-dependent degradation domain (ODD) of HIFα subunits, sufficiently marking HIFα for binding and ubiquitylation via the von Hippel-Lindau (VHL) tumor suppressor protein-containing E3 ubiquitin ligase and subsequent degradation by the 26S proteasome. However, prolyl-hydroxylation in the C-terminal ODD appears to be the predominant and sufficient event in triggering the oxygen-dependent destruction of HIFα, rendering the biological significance of N-terminal ODD proline unclear. Here, we examined seven disease-associated EGLN1 mutations scattered across the catalytic core and showed definitively that all PHD2 mutants have a structural and/or catalytic activity defect as measured by time-resolved nuclear magnetic resonance. Notably, we identified one of the PHD2 mutants, P317R, to retain comparably wild-type capacity to hydroxylate the predominant proline in the C-terminal ODD but had uniquely compromised ability to hydroxylate the N-terminal ODD proline. These findings support the notion that deregulation of HIF ultimately underlies PHD2-driven erythrocytosis and challenge the currently held uncertainty that the N-terminal ODD prolyl-hydroxylation event is dispensable in normal hypoxic signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
- Department of Biochemistry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
- Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
- Department of Medical Biophysics, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
ORCID-Profile: Michael Ohh
Förderung
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Taber, C. C., He, W., Gasmi-Seabrook, G. M. C., Hubert, M., Ferens, F. G., Ikura, M., Lee, J. E., & Ohh, M. (2025). Erythrocytosis-inducing PHD2 mutations implicate biological role for N-terminal prolyl-hydroxylation in HIF1α oxygen-dependent degradation domain. eLife. https://doi.org/10.7554/elife.107121
Vancouver
Taber CC, He W, Gasmi-Seabrook GMC, Hubert M, Ferens FG, Ikura M, et al. Erythrocytosis-inducing PHD2 mutations implicate biological role for N-terminal prolyl-hydroxylation in HIF1α oxygen-dependent degradation domain. eLife. 2025. doi:10.7554/elife.107121
BibTeX
@article{Taber2025,
author = {Taber, Cassandra C and He, Wenguang and Gasmi-Seabrook, Geneviève M C and Hubert, Mia and Ferens, Fraser G and Ikura, Mitsuhiko and Lee, Jeffrey E and Ohh, Michael},
title = {Erythrocytosis-inducing PHD2 mutations implicate biological role for N-terminal prolyl-hydroxylation in HIF1α oxygen-dependent degradation domain},
journal = {eLife},
year = {2025},
doi = {10.7554/elife.107121}
}
EUVIMED